Physician profile
Vijay Kumar
NPI 1689638587
$2,600.22
in general payments reported to CMS, 2019-2025
30 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $90.23 · 2021: $37.08 · 2022: $407 · 2023: $497 · 2024: $583 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $439.19 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals Lp | $268.28 | 2019-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $247.85 | 2019-2023 | Trelegy Ellipta |
| Abbott Laboratories | $196.92 | 2023-2024 | Pressurewire, Freestyle Libre 3 |
| Novo Nordisk INC | $191.86 | 2019-2023 | Ozempic, Rybelsus |
| Viatris Specialty LLC | $182.41 | 2025 | Yupelri |
| Philips North America LLC | $150.38 | 2021-2024 | (8874) Incourage |
| Grifols USA, LLC | $143.47 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.02 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Insmed, INC. | $94.95 | 2021-2025 | Arikayce |
| Corcept Therapeutics | $70.57 | 2025 | Korlym |
| Vertex Pharmaceuticals Incorporated | $49.35 | 2024-2025 | |
| Lundbeck LLC | $44.04 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $30.50 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $29.95 | 2023 | Rexulti |
| Alnylam Pharmaceuticals INC. | $26.00 | 2022 | |
| Pulmonx Corporation | $22.90 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.78 | 2019 | |
| Inspire Medical Systems, INC. | $21.09 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $19.32 | 2025 | Winrevair |
| Allergan, INC. | $18.71 | 2020 | |
| Abbvie INC. | $18.31 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.92 | 2024 | Nuzyra |
| Janssen Pharmaceuticals, INC | $15.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.65 | 2019 | |
| Sumitomo Pharma America, INC. | $13.72 | 2023 | Gemtesa |
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Urovant Sciences INC | $13.48 | 2022 | |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.